chronic%20lymphocytic%20leukemia
CHRONIC LYMPHOCYTIC LEUKEMIA

Chronic lymphocytic leukemia (CLL) is a malignant, chronic lymphoproliferative disorder characterized by proliferation and accumulation of monoclonal B-cells in the bone marrow, peripheral blood, lymph nodes, liver and spleen.

It is the most common form of adult leukemia in the Western world but rare in Asians.

Exact etiology is unknown but usually associated with genetic aberrations and lesions.

 

Chronic%20lymphocytic%20leukemia Signs and Symptoms

Introduction

  • The most common form of adult leukemia in the Western world but less common in Asians

Definition

  • A chronic lymphoproliferative disorder characterized by progressive accumulation of monoclonal B-cell lymphocytes found in the blood and bone marrow

Pathophysiology

  • Commonly associated genetic aberrations include:
    • p53 tumor suppressor gene mutation
    • Chromosomal deletions (eg chromosome 17p, chromosome 11q, chromosome 13q)
    • Chromosomal alteration (trisomy 12)

Signs and Symptoms

  • Enlarged lymph nodes
  • Systemic symptoms: Tiredness, fever, night sweats, weight loss
  • Symptoms of anemia or infection

Risk Factors

  • Chemical exposure
  • Family history - 1st degree relatives
  • Race - higher incidence in Caucasians compared to African Americans and Asians
  • Gender - increased incidence in men compared to women
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
3 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.